NASDAQ · Biotechnology
KYMR (KYMR) Stock
$103.40
-3.37%
NASDAQ: KYMR
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Kymera Therapeutics Shares Fall After RBC Downgrade
MT Newswires · Jul 13, 2026
American Express, Biogen upgraded: Wall Street's top analyst calls
The Fly · Jul 13, 2026
RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk
MT Newswires · Jul 13, 2026
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Motley Fool · Jul 12, 2026
Is Kymera (KYMR) the Best Performing American Stock in June 2026?
Insider Monkey · Jul 9, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held2.10%
Institutions Held115.61%
Institutions Float Held118.09%
Peer Comparison
About KYMR
KYMR is led by CEO Nello Mainolfi, employs 253 people, headquartered in Watertown, US, publicly traded since 2020.
KYMR stock trades at $103.40 with a market capitalization of $8.51B. The stock is valued at a price-to-earnings (P/E) ratio of -23.01, price-to-book of 4.39, price-to-sales of 135.06. Over the past 52 weeks the stock has ranged between $36.65 and $121.08, and currently trades 14.6% below its 52-week high.
On profitability, KYMR generates a return on equity (ROE) of -19.68%, return on capital employed of -22.09%, an operating margin of -894.87%, a net profit margin of -6.12%.